Non-purulent: cellulitis, necrotizing fasciitis, erysipelas. Severe infection: Failed oral antibiotics. Presence of SIRS (â¥ 2 of the following: T > 38Â°C, P > 90, RR > 24, WBC < 4,000 cells/ÏL or > 12,000 cells/ÏL) Immunocompromised patients. Presence of skin sloughing or bullae.
Vaccinium angustifolium fruit and standardized to contain 1.5% anthocyanins. Olive extract is derived from Olea europaea fruit and is standardized to contain. 35% total polyphenols and 1% hydroxytyrosol. Pomegranate extract is derived. from Punica granatum l. fruit and standardized to contain 5% ellagic acid.
Flulaval Quadrivalent comes in a 5mL, multidose vial containing 10 doses (0.5mL each) and a 0.5mL, single-dose, prefilled syringe, while Fluarix Quadrivalent comes in a 0.5mL, single-dose, prefilled syringe. GSK expects to supply up to 40 million doses across both vaccines for the U.S. market in the 2017-18 season. GSK is committed to broad protection against influenza so one hundred percent of GSK supply is quadrivalent. Quadrivalent vaccines are designed to help protect against two main types of flu viruses, A and B, which spread between people and can cause mild to severe illness.